

**Title: Determinants of glycemic control among persons living with type 2 diabetes mellitus attending a district hospital in Ghana**

Authors: Alexander Adjei<sup>1,2</sup>, Kennedy Tettey Coffie Brightson<sup>1</sup>, Michael Matey Mensah<sup>1</sup>, Jemima Osei<sup>1</sup>, Moses Drah<sup>1</sup>, Clement Tetteh Narh<sup>3</sup>, Kwabena Asare<sup>4</sup>, Francis Anto<sup>5</sup>

Institution:

<sup>1</sup>Shai-Osudoku District Hospital, Dodowa, Ghana

<sup>2</sup>Department of Epidemiology, Dodowa Health Research Centre, Dodowa, Ghana

<sup>3</sup>Department of Epidemiology and Biostatistics, Fred N. Binka School of Public Health, University of Health and Allied Sciences, Ho, Ghana

<sup>4</sup>Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom

<sup>5</sup>Department of Epidemiology and Disease Control, School of Public Health, College of Health Sciences, University of Ghana, Accra, Ghana

Corresponding author (Email address): [caesar306@yahoo.com](mailto:caesar306@yahoo.com) (A. A)

## **Abstract**

### **Background**

Diabetes mellitus is a growing public health emergency with prevalence in sub-Saharan Africa expected to experience the highest increase by 2045. The cornerstone of diabetes management is glycemic control, a complex process with different contributing factors. This study determines the level of glycemic control and the associated individual factors among type 2 diabetes mellitus (T2DM) patients.

### **Methods**

A cross-sectional descriptive study was conducted at the Shai-Osudoku District Hospital from October to December 2022. A structured questionnaire was used to collect data on socio-demographic characteristics, lifestyle modifications, co-morbidities, adherence to medication and diet regimens and duration of diabetes. Anthropometric and glycated hemoglobin (HbA1c) measurements were taken. Chi-squared and multivariate logistic regression analyses were carried out to determine factors associated with glycemic control at 95% confidence levels.

### **Results**

A total of 227 patients participated in this study. The majority of the participants were females (77.97%) and the mean ( $\pm$ SD) age was  $60.76 \pm 12.12$  years. Good glycemic control (HbA1c < 7%) among the participants was 38.77% (n=88) and the median HbA1c was 7.5% (IQR: 6.5% to 9.4%). Significant factors associated with good glycemic control were eating healthy meals (AOR: 4.78, 95% CI: 1.65, 13.88: p=0.004), oral hypoglycemic agents alone (AOR: 15.71, 95% CI: 1.90, 129.44: p=0.010) and those with previously good glycemic control (AOR: 4.27, 95% CI: 2.16, 8.43: <0.001).

## **Conclusion**

This study showed low levels of good glyceimic control among T2DM patients at the primary care level in Ghana. Healthy eating, oral hypoglycemic agents and those with previously normal HbA1c were associated with glyceimic control.

Keywords: Glyceimic control, Type 2 diabetes mellitus, Shai-Osudoku District Hospital

## Introduction

The increasing burden of non-communicable diseases especially Type 2 diabetes mellitus (T2DM) has become a public health emergency (1). The estimated 10.5% global prevalence of diabetes among 20-79-year-olds in 2021 is expected to increase to 12.2% by 2045. Middle-income countries are expected to experience the highest relative increase compared to high and low-income countries over this period. The African region had the lowest estimated prevalence of 4.5% in 2021 but is expected to witness the highest relative increase in persons living with diabetes by 2045 (2). The prevalence of T2DM in Ghana was estimated to be 6.46% among adults in 2018 (3), much higher than the African average.

Glycemic control remains the basis of diabetes management but evidence shows poor levels of control worldwide with an even higher burden in low and middle-income countries (4–9). Studies in Ghana have reported the prevalence of poor glycemic control to be more than 59% using glycated hemoglobin levels (HbA1c) of 7% and above (10,11).

The consequences of this high burden of poor glycemic control are macro and microvascular complications such as retinopathy, nephropathy, stroke and ischemic heart diseases (12). These lead to high morbidity with poor quality of life and mortality as well as the economic burden on these persons and the health system (13,14). Glycated hemoglobin level which measures the average plasma glucose over the previous three months correlates well with these macro and microvascular complications (15).

Different factors have been demonstrated to influence glycemic control from socio-demographic (16–18) to socio-economic characteristics (10,19–21). Others factors include co-morbidities and

lifestyle modification (10,22–25), dietary and medication adherence (6,16,26), type of anti-diabetic medication used by patients (27,28) and duration of diabetes (5,29).

Glycemic control can be a complex and difficult process with different individual factors contributing to it. Knowing these factors within the context of the local settings will enhance policy formulation that seeks to improve the health outcomes of T2DM patients and prevent and reduce complications. This will improve patients' quality of life and decrease the financial burden on the scarce resources of the health sector in low and middle-income countries. This study aimed to assess the glycemic level and categorize the individual factors that influence glycemic control among T2DM patients attending clinic at Shai-Osudoku District Hospital.

## **Methods**

### **Study design**

A cross-sectional descriptive study was conducted to determine factors associated with glycemic control among Type 2 diabetes mellitus patients attending the out-patient unit of the Shai-Osudoku District Hospital from October to December 2022. Patients were sequentially enrolled on the study and face-to-face interviews were conducted. Data on socio-demographic characteristics, lifestyle and history of diabetes were collected from the patients using a structured questionnaire. Anthropometric and glycated hemoglobin measurements were also done. The patients' clinic records were reviewed and data on previous HbA1c levels and medications being taken extracted.

### **Study site**

The study was carried out at the Shai-Osudoku District Hospital (SODH), located in Dodowa, the capital of Shai-Osudoku District of the Greater Accra Region, Ghana. It is a 140-bed capacity hospital with both in- and out-patient facilities and laboratory services. The hospital has an average out-patient attendance of 60 000 annually and runs a chronic diseases care clinic for diabetic and hypertensive patients. It serves the district's population of about 105,600 (according to Ghana's 2020 population and housing census). The hospital also serves as the main referral centre for the lower-level health facilities in the surrounding peri-urban and rural communities. The district has four government health centres, 10 Community-based Health Planning and Services (CHPS) compounds, one private hospital, one mission hospital and four private clinics. The inhabitants are mainly subsistence farmers, fishermen, artisanal workers, craftsmen, and petty traders. There are a few civil servants, mainly migrant employees of government ministries, departments, and agencies.

## **Sample size estimation and sampling**

Yamane's formula [ $n = N / (1 + Ne^2)$  where  $n$  = the required sample size,  $N$  = the total population and  $e$  = the margin of error of 0.05] was used to estimate the required minimum sample size based on the population of 240 visiting the diabetic clinic regularly. Using a 5% margin of error and 5% non-response rate, a sample size of 158 patients was estimated. To increase the statistical power and allow for further sub-group analysis, however, all Type 2 diabetes mellitus patients who consented to be part of the study were sequentially enrolled.

## **Inclusion/exclusion criteria**

All Type 2 diabetes mellitus patients who visit the study facility regularly and consented to be part of the study were eligible for participation except those who were seriously ill.

## **Data collection tool**

A questionnaire was developed specifically for this work, incorporating the Perceived Dietary Adherence Questionnaire (PDAQ) for persons living with Type 2 diabetes mellitus and the Morisky Green Levine medication adherence scale. The questionnaire had four main sections. The first section captured data on the background characteristics of study participants including age, sex, marital status, employment status, level of education, place of residence, household size, sex of head of household, and lifestyle characteristics. The second section captured data on medical history including duration of diabetes, existence of comorbidities and type of antidiabetic medication being taken. The third section collected data on the patient's perceived dietary adherence. This section consisted of nine questions structured to capture a nutritional therapy guideline that was adapted to the food items in our local settings consisting primarily of carbohydrates, fats and oils, fruits and vegetables. The fourth section captured data on medication adherence based on the Morisky Green Levine medication scale. Information collected included

whether patient sometimes forgot to take his or medications, whether in the past two weeks, there was any day patient did not take his or her medications and whether patient took his or her medications the day before the study.

## **Data collection procedures**

### ***Interviews and data extraction***

Face-to-face interviews lasting for about 20 minutes were carried out with the study participants after their scheduled clinic review using the structured questionnaire. The interviews were done by trained research officers following standard operating procedures. Data were collected on demographic and lifestyle characteristics, comorbidities and duration of diagnosis of diabetes mellitus. Dietary and drug adherence information were also collected from the patients and updated using clinic records as source documents where necessary.

### ***Weight measurement***

Patients were weighed using the Seca dial column weighing scale (JACKERMAC GERMANY) with an attached stadiometer placed on an even surface and adjusted to zero. They were weighed standing straight on the scale completely with weight evenly distributed between their feet placed in the center of the scale, not touching anything, without shoes and the pockets emptied. The recorded measurement was checked for accuracy and weight measured to the nearest 100g.

### ***Height measurement***

Patients stood straight with feet together on the stadiometer without shoes. The patient's knees, back and neck were straightened, back close to the scale and the head lever placed on top of the head. The height of the patient was measured from the level recorded from the scale by the study nurse. Height was measured to the nearest 0.1cm and recorded values were checked for accuracy.



## *Assessing HbA1c*

A point-of-care calibrated automated analyzer (A1 Care™) was used to estimate the HbA1c levels. The automated HbA1c analyzer uses cartridge which has a sample collection device and a lysing buffer cell. The sample collector which has a handle was removed from the cartilage and used to collect about 2.5µl of anti-coagulated venous blood from an EDTA tube. The sample collector was gently placed and positioned inside the cartilage which was then completely inserted into the reaction chamber of the analyzer. The sample collector handle was gently pressed down to rupture the lysing buffer and the reaction chamber closed. The sample was analyzed and the HbA1c results displayed within 5 minutes.

## **Data management and analysis**

All completed questionnaires were checked for missing information and errors daily. The data were entered and cleaned using Epi Info Version 7. Statistical analyses were done using STATA version 17. Descriptive statistics were used to present data as frequencies with their corresponding percentages. The proportion of patients with good glycemic control (HbA1c <7%) was determined and its distribution across the independent variables was presented in cross-tabulations.

The weight and height were used to calculate the body mass index (BMI) of patients. Weight in kilograms was divided by the square of the height in meters. BMI was categorized as underweight (<18.5kg/m<sup>2</sup>), normal weight (18.5-24.9kg/m<sup>2</sup>), overweight (25.0-29.9kg/m<sup>2</sup>), and obese (≥30.0kg/m<sup>2</sup>). Medication adherence was assessed based on four main questions with Yes or No responses. The questions were negatively coded. The lower the total score, the more adherent the patient was to the medication regimen. This was categorized as low (score of 3-4), moderate (score of 1-2) and high (score of 0) adherence.

Spearman rank correlation was used to determine the relationship between glycemic control and continuous variables. The Chi-square test was used to determine association between glycemic control and categorical variables. One-way analysis of variance was done for categorical variables with more than two groups. Fisher's exact test and Wilcoxon rank-sum test were used as non-parametric measures. Multivariate logistic regression was conducted to determine the strength of association between the individual-level factors and glycemic control at 95% level of confidence.

### **Ethical consideration**

The study protocol, data collection tool and consent form were reviewed and approved by the Ethics Review Committee (GHS-ERC) of the Ghana Health Service with Protocol ID GHS-ERC 064/09/22. Written informed consent was obtained from all study participants before enrollment into the study, the confidentiality of patient identity and information was respected. The study was conducted under Good Clinical Practices and Helsinki Declaration for biomedical research on human subjects.

## Results

### Demographic and clinical characteristics of patients

A total of 230 Type 2 diabetes mellitus patients visited the clinic during the study period and consented to participate in the study. Out of the 230 patients screened, 227 (98.70%) met the inclusion criteria and were enrolled and included in the analyses. The mean age of the enrolled patients was 60.76 ( $\pm$  12.12) years with the majority of them being female (77.97%). Most of the patients (62.11%) were married and 77.54% had completed secondary or higher education. One hundred and fourteen (50.22%) of them were employed and 69.16% lived in urban parts of the district. The majority of the patients (71.11%) were either overweight or obese. Almost 60% of the patients have been living with diabetes mellitus for five or more years and over 74% do not exercise at all or exercise only once in a while. Over 85% were on oral hypoglycemic agents alone and more than half of the patients were adhering to medication based on the Morisky Green Levine's medication adherence score (Table 1).

**Table 1: Demographic and clinical characteristics of study patients**

<b>Characteristics</b>	<b>Frequency</b>	<b>Percentage (%)</b>
<b>Age Group (years)</b>		
<60	101	44.49
≥60	126	55.51
<b>Sex</b>		
Female	177	77.97
Male	50	20.03
<b>Marital status</b>		
Single/widowed/divorced	86	37.88
Married/living together	141	62.11
<b>Level of education</b>		
No formal/Primary education	51	22.46
Secondary/Tertiary education	176	77.54
<b>Employment status</b>		
Employed	114	50.22
Not employed	70	30.84
Retired	43	18.94
<b>Residence</b>		
Peri-urban	39	17.18
Rural	31	13.66
Urban	157	69.16
<b>BMI of patients (N=225)</b>		
Underweight	4	1.78
Normal	61	27.11
Overweight	68	30.22
Obese	92	40.89
<b>Duration of Diabetes (years)</b>		
<5	91	40.09
5-10	77	33.92
>10	59	25.99
<b>Level of exercise</b>		
No exercise	68	29.96
Not regular/once in a while	102	44.93
Once to five times a week	57	25.11
<b>Type of anti-diabetic agents</b>		
Oral hypoglycemic agents	195	85.90
Insulin	12	5.29
Both	20	8.81
<b>Adherence to medication (MGL)</b>		
Low adherence	22	10.13
Medium adherence	76	33.48
High adherence	128	56.39

## **Level of glycemic control among T2DM patients**

Most of the patients (61.23%, 139/227) had poor glycemic control ( $\text{HbA1c} \geq 7\%$ ). The measured HbA1c of patients were positively skewed with a median HbA1c of 7.5% (IQR: 6.5% - 9.4%) (Fig. 1). There was no statistically significant difference in the median HbA1c among males and females using the Wilcoxon rank-sum test ( $p=0.2402$ ). There was an inverse significant relationship between HbA1c and age of patients from the Spearman rank correlation ( $r=-0.2205$ ,  $p < 0.001$ ). There was a statistically significant difference comparing HbA1c by the type of anti-diabetic agents ( $p < 0.001$ ) based on one-way analysis of variance (ANOVA).

## **Association between glycemic control and socio-demographic characteristics**

A higher proportion of patients (70.75%) aged below 60 years had poor glycemic control compared to those aged 60 years and above (52.89%). A lower proportion (49.54%) of patients who usually eat healthy meals had poor glycemic control compared to 67.09% and 82.05% of those who only sometimes eat healthy meals and those who did not often eat healthy meals respectively. Using the perceived dietary adherence scale, 62.22% of those with low level of adherence had poor glycemic control compared to 57.14% of those with high level of adherence.

There was a statistically significant association between glycemic control and the age of patients ( $p=0.006$ ), marital status ( $p=0.032$ ), the type of anti-glycemic agent ( $p < 0.001$ ), eating healthy meals ( $p < 0.001$ ), and having a previously good glycemic level ( $p < 0.001$ ) based on Chi-square test (Table 2).

**Table 2: Association between demographic characteristics and glycemic control**

Characteristics	Good Glycemic control (%)	Poor Glycemic control (%)	$\chi^2$	P - value
<b>Age group (years)</b>			7.59	<b>0.006</b>
<60	31 (29.25)	75 (70.75)		
≥60	57 (47.11)	64 (52.89)		
<b>Sex</b>			0.04	0.839
Female	68 (38.42)	109 (61.58)		
Male	20 (40.00)	30 (60.00)		
<b>Marital status</b>			4.63	<b>0.032</b>
Single/widow/divorced	41 (47.67)	45 (52.33)		
Married/living together	47 (33.33)	94 (66.67)		
<b>BMI (N=225)</b>			7.17	0.062 <sup>a</sup>
Underweight	1 (25.00)	3 (75.00)		
Normal	22 (36.07)	39 (63.93)		
Overweight	35 (51.47)	33 (48.53)		
Obese	29 (31.52)	63 (68.48)		
<b>Duration of diabetes</b>			3.61	0.165
Less than 5years	42 (46.15)	49 (53.85)		
5-10years	27 (35.06)	50 (64.94)		
More than 10years	19 (32.20)	40 (67.80)		
<b>Type of anti-diabetic agents</b>			19.93	<b>&lt;0.001<sup>a</sup></b>
Oral hypoglycemic agents	87 (44.62)	108 (55.38)		
Insulin/Both	1 (3.13)	31 (96.88)		
<b>Drug adherence (MGL)</b>			2.31	0.312
Low adherence	6 (26.09)	17 (73.91)		
Medium adherence	28 (36.84)	48 (63.16)		
High adherence	54 (42.19)	74 (57.81)		
<b>Eating healthy meals</b>			14.54	<b>&lt;0.001</b>
Usually	55 (50.46)	54 (49.54)		
Sometimes	26 (32.91)	53 (67.09)		
Not often	7 (17.95)	32 (82.05)		
<b>Perceived Dietary Adherence Questionnaire scale</b>			1.56	0.212
Low adherence	40 (34.78)	75 (62.22)		
High adherence	48 (42.86)	64 (57.14)		
<b>Previous HbA1c</b>			32.67	<b>&lt;0.001</b>
Good control	47 (67.14)	23 (32.86)		
Poor control	38 (26.39)	106 (73.61)		

<sup>a</sup>Fisher's exact test p-value

## Multivariable analysis of significant independent factors

The multivariable logistic regression analysis revealed that patients who usually eat healthy meals (aOR: 4.78, 95% CI: 1.65, 13.88), are on oral hypoglycemic agents alone (aOR: 15.71, 95% CI: 1.90, 129.44) and those with previously good glycemic control (aOR: 4.27, 95% CI: 2.16, 8.43) had good glycemic control in this study (Table 3).

**Table 3: Multivariable logistic regression for determinant of glycemic control**

Characteristics	Unadjusted		Adjusted	
	OR (95% CI)	P-value	OR (95% CI)	P-value
<b>Age group in years</b>				
60 and below	Ref		Ref	
Above 60	2.16 (1.24, 3.74)	<b>0.006</b>	1.37 (0.71, 2.62)	0.346
<b>Marital status</b>				
Single/widow/divorced	Ref		Ref	
Married/living together	0.55 (0.32, 0.95)	<b>0.032</b>	0.55 (0.29, 1.04)	0.067
<b>Eating healthy meal</b>				
Not healthy meals	Ref		Ref	
Sometimes	2.24 (0.87, 5.76)	0.093	1.84 (0.62, 5.44)	0.271
Healthy meals	4.66 (1.89, 11.45)	<b>0.001</b>	4.78 (1.65, 13.88)	<b>0.004</b>
<b>Type of anti-diabetic agents</b>				
Both/Insulin	Ref		Ref	
Oral hypoglycemic agents	24.97(3.34, 186.61)	<b>0.002</b>	15.71 (1.90, 129.44)	<b>0.010</b>
<b>Previous HbA1c</b>				
Poor control	Ref		Ref	
Good control	5.70 (3.06, 10.61)	<b>&lt;0.001</b>	4.27 (2.16, 8.43)	<b>&lt;0.001</b>

## Discussion

This study assessed patient factors associated with glycemic control among type 2 diabetes mellitus (T2DM) patients receiving care at a district hospital in Ghana, West Africa. The study found the level of glycemic control among the patients to be poor (39%), significantly influenced by poor eating habits. The use of insulin alone or in combination with an oral hypoglycemic agent did not appear to improve glycemic control in patients with a history of poor control.

Varying levels of glycemic control have been reported from different studies and among different populations, with the prevalence of poor control ranging from 45 - 93% among T2DM patients (9). The high prevalence of poor glycemic control (61%) found in our current study is within this range reported by Bin Rakhis and colleagues in their systematic review and also within the range 39-69 % reported by Swaray and colleagues in Ghana for the period 2015-2021 (11). Similar levels of poor glycemic control, 61% (6) and 65% (30), have been reported in Ethiopia. Studies in Nigeria (40%, Ibrahim et al., 2021) and some industrialized countries, China (50%, (25) and the United States of America (28%, Devineni et al., 2024), have however reported much lower levels of poor glycemic control.

Poor glycemic control has been associated with several patient and medication factors including having high body mass index and being on insulin therapy. Similarly, some behavioural factors such as high level of physical activity and eating healthy meals (Djonor, et al, 2021), have been reported to influence good glycemic control. As indicated, the main patient factor found to be associated with good glycemic control in our current study is eating healthy meals. According to Sainsbury, et al. (2018), carbohydrate-restricted diet can lead to a reduction in HbA1c and therefore good glycemic control.



Managing T2DM involves a multi-disciplinary team and the role of dieticians is as important as that of clinicians in improving glycemic control (31). That is, dietary control is an important component of the therapeutic lifestyle modification in the management of T2DM (7,23). Dietary guidelines have therefore been established in terms of carbohydrates, especially fiber-rich, proteins and fats for persons living with T2DM (32,33). These guidelines need to be individualized in a patient-centered manner taking into consideration the socio-economic implications of such nutritional therapy.

The use of oral hypoglycemic agents alone showed some association with glycemic control in our current study. Previous studies have reported conflicting results with choice of medication and glycemic control among T2DM. The findings in this study is consistent with an earlier study in Ghana where T2DM patients on insulin therapy were significantly associated with poor glycemic control (10). Other studies in Greece found the use of injectables (insulin) to be associated with good glycemic control compared to oral hypoglycemic agents alone or in combination with injectables (28). Ghabban and his colleagues in Saudi Arabia also found the use of combined therapy to be associated with poor glycemic control compared to insulin therapy alone (27).

The use of insulin in T2DM mostly happens late in the management because of the pathophysiology, the relative insulin deficiency against a background of peripheral resistance (34). The disease progression leads to the gradual loss of the  $\beta$ -cell secretory functions (35), leading to T2DM being reliant on insulin injection in the latter stages to achieve glycemic control. The use of insulin injection comes with low compliance with its consequence on glycemic control (36) and sometimes difficulty in storage especially when dealing with patients with low socioeconomic status. Improving compliance through patient education on the proper use of injectables and

monitoring HbA1c targets on follow-up visits will help address patient problems, phobias and myths associated with insulin injection.

Another significant factor identified in this study was patients past good glycemc history. This underlines the comprehensive, continuous and coordinated management of T2DM with targeted glycemc control while addressing challenges associated with complications, drug adverse effects and comorbidities.

## **Limitations of the study**

Glycated hemoglobin levels could be affected by anaemia and hemoglobin variants like sickle cell traits and Glucose-6-phosphate dehydrogenase deficiency. These were not assessed and therefore not controlled for in the analysis. Information on dietary and medication adherence was assessed using adopted tools which could be affected by recall bias. This is a cross-sectional study and thus causal relationship could not be established. These limitations notwithstanding the findings of this study can serve as a guide in the management of T2DM patients.

## **Conclusion**

This study found a high level of poor glycemc control among T2DM patients receiving care at a district hospital in Ghana which was significantly associated with eating unhealthy foods. Strong collaboration among attending clinicians and dieticians could help improve care for such patients.

## **Acknowledgement:**

The authors wish to acknowledge the management, and staff of Shai-Osudoku District Hospital, especially Dr. Akude, Dr. Majorie Nii Koi, the nurses, and patients at the Diabetic Clinic.

## **Authors contribution:**

**Conceptualization:** Alexander Adjei, Francis Anto

**Data curation:** Alexander Adjei, Michael Matey Mensah, Jemima Osei, Moses Drah, Clement Tetteh Narh, Kwabena Asare

**Formal analysis:** Alexander Adjei, Michael Matey Mensah, Moses Drah, Clement Tetteh Narh, Kwabena Asare

**Investigation:** Alexander Adjei, Kennedy Tettey Coffie Brightson, Michael Matey Mensah, Jemima Osei, Moses Drah, Francis Anto

**Methodology:** Alexander Adjei, Clement Tetteh Narh, Kwabena Asare, Francis Anto

**Resources:** Alexander Adjei, Kennedy Tettey Coffie Brightson

**Supervision:** Francis Anto

**Validation:** Alexander Adjei, Kennedy Tettey Coffie Brightson, Michael Matey Mensah, Jemima Osei, Moses Drah, Clement Tetteh Narh, Kwabena Asare, Francis Anto

**Visualization:** Alexander Adjei, Kennedy Tettey Coffie Brightson, Michael Matey Mensah, Jemima Osei, Moses Drah, Clement Tetteh Narh, Kwabena Asare, Francis Anto

**Writing – original draft:** Alexander Adjei, Kennedy Tettey Coffie Brightson, Kwabena Asare, Francis Anto

**Writing – review & editing:** Alexander Adjei, Kennedy Tettey Coffie Brightson, Michael Matey Mensah, Jemima Osei, Moses Drah, Clement Tetteh Narh, Kwabena Asare, Francis Anto

## References

1. Kharroubi AT. Diabetes mellitus: The epidemic of the century. *World J Diabetes*. 2015;6(6):850.
2. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract* [Internet]. 2022;183:109119. Available from: <https://doi.org/10.1016/j.diabres.2021.109119>
3. Asamoah-Boaheng M, Sarfo-Kantanka O, Tuffour AB, Eghan B, Mbanya JC. Prevalence and risk factors for diabetes mellitus among adults in Ghana: A systematic review and meta-analysis. *Int Health*. 2019;11(2):83–92.
4. Wolde HF, Derso T, Biks GA, Yitayal M, Ayele TA, Gelaye KA, et al. High hidden burden of diabetes mellitus among adults aged 18 years and above in urban northwest Ethiopia. *J Diabetes Res*. 2020;2020:1–9.
5. Aschner P, Galstyan G, Yavuz DG, Litwak L, Gonzalez-Galvez G, Goldberg-Eliaschewitz F, et al. Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion. *Diabetes Ther* [Internet]. 2021;12(5):1491–501. Available from: <https://doi.org/10.1007/s13300-021-00997-0>
6. Gudisa B, Gemechis B. The Incidence and Predictors of Poor Glycemic Control among Adults with Type 2 Diabetes Mellitus in Ambulatory Clinic of Mettu Karl Referral Hospital, South Western, Ethiopia: A Prospective Cross Sectional Study. *Int Arch Endocrinol Clin Res*. 2021;7(1):1–9.
7. Rahman M, Nakamura K, Hasan SMM, Seino K, Mostofa G. Mediators of the association between low socioeconomic status and poor glycemic control among type 2 diabetics in Bangladesh. *Sci Rep* [Internet]. 2020;10(1):1–13. Available from: <http://dx.doi.org/10.1038/s41598-020-63253-8>
8. Radwan M, Elsous A, Al-Sharif H, Abu Mustafa A. Glycemic control among primary care patients with type 2 diabetes mellitus in the Gaza Strip, Palestine. *Ther Adv Endocrinol Metab*. 2018;9(1):3–14.
9. Bin Rakhis SA, AlDuwayhis NM, Aleid N, AlBarrak AN, Aloraini AA. Glycemic Control for Type 2 Diabetes Mellitus Patients: A Systematic Review. *Cureus*. 2022;14(6):6–13.
10. Djonor SK, Ako-Nnubeng IT, Owusu EA, Akuffo KO, Nortey P, Agyei-Manu E, et al. Determinants of blood glucose control among people with Type 2 diabetes in a regional hospital in Ghana. *PLoS One* [Internet]. 2021;16(12 December):1–19. Available from: <http://dx.doi.org/10.1371/journal.pone.0261455>
11. Swaray SM, Tetteh J, Djonor SK, Ekem- Ferguson G, Clottey RY, Yacoba A et al. Changes in trends and patterns of glycaemic control at Ghana ' s National Diabetes Management and Research Centre during the era of the COVID-19 pandemic. *PLOS Glob Public Heal* [Internet]. 2023;3(6):1–19. Available from:

<http://dx.doi.org/10.1371/journal.pgph.0002024>

12. Borgharkar SS, Das SS. Real-world evidence of glycemic control among patients with type 2 diabetes mellitus in India: The TIGHT study. *BMJ Open Diabetes Res Care*. 2019;7(1):2–8.
13. Ali, Sarah Naz, Tam Dang-Tan WJ. Evaluation of the clinical and economic burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the United States. *Adv Ther* [Internet]. 2020;37:869–82. Available from: <https://doi.org/10.6084/>
14. Bain SC, Bekker Hansen B, Hunt B, Chubb B, Valentine WJ. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. *J Med Econ* [Internet]. 2020 [cited 2022 Mar 17];23(1):98–105. Available from: <https://www.tandfonline.com/action/journalInformation?journalCode=ijme20>
15. Jean-Marie E. Diagnosis and classification of diabetes mellitus [Internet]. 2nd ed. *Encyclopedia of Endocrine Diseases*. Elsevier Inc.; 2018. 105–109 p. Available from: <http://dx.doi.org/10.1016/B978-0-12-801238-3.65822-1>
16. Ibrahim AO, Agboola SM, Elegbede OT, Ismail WO, Agbesanwa TA, Omolayo TA. Glycemic control and its association with sociodemographics, comorbid conditions, and medication adherence among patients with type 2 diabetes in southwestern Nigeria. *J Int Med Res*. 2021;49(10):1–13.
17. Tefera YG, Gebresillassie BM, Emiru YK, Yilma R, Hafiz F, Akalu H, et al. Diabetic health literacy and its association with glycemic control among adult patients with type 2 diabetes mellitus attending the outpatient clinic of a university hospital in Ethiopia. *PLoS One* [Internet]. 2020;15(4):1–15. Available from: <http://dx.doi.org/10.1371/journal.pone.0231291>
18. Yosef T, Nureye D, Tekalign E. Poor glycemic control and its contributing factors among type 2 diabetes patients at adama hospital medical college in east Ethiopia. *Diabetes, Metab Syndr Obes Targets Ther*. 2021;14:3273–80.
19. Babaniamansour S, Aliniagerdroudbari E, Niroomand M. Glycemic control and associated factors among Iranian population with type 2 diabetes mellitus: a cross-sectional study. *J Diabetes Metab Disord*. 2020;19(2):933–40.
20. Asmelash D, Abdu N, Tefera S, Baynes HW, Derbew C. Knowledge, Attitude, and Practice towards Glycemic Control and Its Associated Factors among Diabetes Mellitus Patients. *J Diabetes Res*. 2019;2019:1–9.
21. Cheng LJ, Wang W, Lim ST, Wu VX. Factors associated with glycaemic control in patients with diabetes mellitus: A systematic literature review. Vol. 28, *Journal of Clinical Nursing*. Blackwell Publishing Ltd; 2019. p. 1433–50.

22. Mobula LM, Sarfo FS, Carson KA, Burnham G, Arthur L, Ansong D, et al. Predictors of glycemic control in type-2 diabetes mellitus: Evidence from a multicenter study in Ghana. *Transl Metab Syndr Res* [Internet]. 2018;1:1–8. Available from: <https://doi.org/10.1016/j.tmsr.2018.09.001>
23. Kakade AA, R Mohanty I, Rai S. Assessment of factors associated with poor glycemic control among patients with Type II Diabetes mellitus. *Integr Obes Diabetes*. 2018;4(3):1–6.
24. Almetwazi M, Alwhaibi M, Balkhi B, Almohaini H, Alturki H, Alhawassi T, et al. Factors associated with glycemic control in type 2 diabetic patients in Saudi Arabia. *Saudi Pharm J* [Internet]. 2019;27(3):384–8. Available from: <https://doi.org/10.1016/j.jsps.2018.12.007>
25. Zhu HT, Yu M, Hu H, He QF, Pan J, Hu RY. Factors associated with glycemic control in community-dwelling elderly individuals with type 2 diabetes mellitus in Zhejiang, China: A cross-sectional study. *BMC Endocr Disord*. 2019;19(1):1–11.
26. Sainsbury E, Kizirian N V., Partridge SR, Gill T, Colagiuri S, Gibson AA. Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes: A systematic review and meta-analysis. *Diabetes Res Clin Pract* [Internet]. 2018;139:239–52. Available from: <https://doi.org/10.1016/j.diabres.2018.02.026>
27. Ghabban SJ, Althobaiti B, Farouk I, Al Hablany M, Ghabban A, Alghbban R, et al. Diabetic Complications and Factors Affecting Glycemic Control Among Patients With Type II Diabetes Mellitus Attending the Chronic Illness Clinics at Tabuk, Saudi Arabia. *Cureus*. 2020;12(11):1–9.
28. Souliotis K, Koutsovasilis A, Vatheia G, Golna C, Nikolaidi S, Hatziagelaki E, et al. Profile and factors associated with glycaemic control of patients with type 2 diabetes in Greece : results from the diabetes registry. *BMC Endocr Disord*. 2020;20(16):1–10.
29. Alzaheb RA, Altemani AH. The prevalence and determinants of poor glycemic control among adults with type 2 diabetes mellitus in Saudi Arabia. *Diabetes, Metab Syndr Obes Targets Ther*. 2018;11:15–21.
30. Fekadu G, Bula K, Bayisa G, Turi E, Tolossa T, Kasaye HK. Challenges and factors associated with poor glycemic control among type 2 diabetes mellitus patients at Nekemte referral hospital, Western Ethiopia. *J Multidiscip Healthc*. 2019;12:963–74.
31. Sunuwar DR, Nayaju S, Dhungana RR, Karki K, Singh Pradhan PM, Poudel P, et al. Effectiveness of a dietician-led intervention in reducing glycated haemoglobin among people with type 2 diabetes in Nepal: a single centre, open-label, randomised controlled trial. *Lancet Reg Heal - Southeast Asia* [Internet]. 2023;100285. Available from: <https://doi.org/10.1016/j.lansea.2023.100285>
32. American Diabetes Association. Standards of medical care in Diabetes -2018. *J Clin Appl Res Educ*. 2018;41(January):S1–159.
33. Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al.

- Nutrition therapy recommendations for the management of adults with diabetes. *Diabetes Care*. 2014;37(SUPPL.1):120–43.
34. American Diabetes Association. Classification and Diagnosis of Diabetes : Standards of Medical Care in Diabetes — 2022. *Diabetes Care*. 2022;45(Suppl):S17–38.
  35. Petersmann A, Müller-Wieland D, Müller UA, Landgraf R, Nauck M, Freckmann G, et al. Definition, Classification and Diagnosis of Diabetes Mellitus. *Exp Clin Endocrinol Diabetes*. 2019;127:S1–7.
  36. Liatis S, Iraklianiou S, Kazakos K, Mastorakos G, Milios K, Mouslech Z, et al. A Greek registry of current type 2 diabetes management, aiming to determine core clinical approaches, patterns and strategies. *BMC Endocr Disord*. 2019;19(1):1–14.

### **Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.


### **Conflict of Interest**

The authors declare that they do not have any conflicts of interest.

### **Funding:**

No funding was received for this study.

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.18.24310634>; this version posted July 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).



**Fig. 1: Graph showing the distribution of glycated hemoglobin of patients**